Drug Trial Radar · NCT06795048
A Study to Determine the Efficacy, Safety, and Durability of Faricimab in Participants With Neovascular Age-Related Macular Degeneration
Last checked: Nov 20, 2026Latest source record: Oct 27, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
274
Planned (sponsor's estimate)
Start
Mar 14, 2025
Primary completion
Oct 16, 2026
Study completion Sep 20, 2027
Sponsor
- Lead sponsor
- Hoffmann-La RocheRoche (Genentech) (RHHBY)
- Sponsor type
- Industry
- First posted
- Jan 27, 2025
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 50 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study is a Phase IIIb/IV, multicenter, randomized, two-arm, open-label 100-week study to investigate the efficacy, safety, and durability of intravitreal 6-mg faricimab administered at up to 24-week intervals in patients with neovascular age-related macular degeneration (nAMD) that are treatment-naïve in the study eye.
Conditions
- Neovascular Age-related Macular Degeneration (nAMD)
Interventions
FaricimabDrug
Participants will receive 6-mg faricimab intravitreal (IVT) injections in the study eye according to the dosing regimen for the study arm to which they are randomized.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change from Baseline in Best-Corrected Visual Acuity (BCVA) Score Averaged Over Weeks 44, 48, and 52Time frame: Baseline and average of Weeks 44, 48, and 52
Locations
67 sites in 12 countries. Site status is shown where the registry gives one.
Orange County Retina Medical Group
Santa Ana, California
Florida Retina Institute
Orlando, Florida
Ctr for Retina & Macular Dis
Winter Haven, Florida
Retinal Vitreal Consultants
Chicago, Illinois
University Retina and Macula Associates, PC
Lemont, Illinois
New England Retina Consultants
Springfield, Massachusetts
Sierra Eye Associates
Sparks, Nevada
Retina Associates of New Jersey
Teaneck, New Jersey
Vision Research Center at Eye Associates of New Mexico
Albuquerque, New Mexico
Charles Retina Institute
Germantown, Tennessee
Retina Consultants of Texas
Schertz, Texas
Strathfield Retina Clinic
Strathfield, New South Wales, Australia
Sydney Eye Hospital
Sydney, New South Wales, Australia
Adelaide Eye and Retina Centre
Adelaide, South Australia, Australia
Centre For Eye Research Australia
East Melbourne, Victoria, Australia
Retina Specialists Victoria
Rowville, Victoria, Australia
The Lions Eye Institute
Nedlands, Western Australia, Australia
St. Joseph's Health Care
London, Ontario, Canada
Retina Institute of Ottawa
Ottawa, Ontario, Canada
Toronto Retina Institute
Toronto, Ontario, Canada
Toronto Western Hospital
Toronto, Ontario, Canada
Hopital du Saint Sacrement
Québec, Quebec, Canada
Peking University People's Hospital
Beijing, China
West China Hospital of Sichuan University
Chengdu, China
Sichuan Provincial People's Hospital
Chengdu, China
Zhongshan Ophthalmic Center, Sun Yat-sen University
Guangzhou, China
Eye and ENT hospital, Fudan University
Shanghai, China
Tongji Hosp, Tongji Med. Col, Huazhong Univ. of Sci. & Tech
Wuhan, China
Centre Retine Gallien
Bordeaux, France
Hopital Edouard Herriot - CHU Lyon
Lyon, France
Centre Ophtalmologique de L'Odeon
Paris, France
Hopital Lariboisiere
Paris, France
Centres Ophtalmologique St Exupéry
Saint-Cyr-sur-Loire, France
Clinique de l'Union
Saint-Jean, France
Augenzentrum Prof. Koch GmbH
Frankfurt, Germany
Medizinische Hochschule Hannover, Klinik für Augenheilkunde
Hanover, Germany
Augenzentrum am St Franziskus-Hospital
Münster, Germany
Universitatsklinikum Ulm, Augenklinik und Poliklinik
Ulm, Germany
Universitätsklinikum Würzburg, Augenklinik und Poliklinik
Würzburg, Germany
Azienda ospedaliero universitaria Policlinico Riuniti di Foggia;SC Oculistica
Foggia, Apulia, Italy
Showing 40 of 67 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.